市场调查报告书
商品编码
1368672
哺乳动物细胞发酵技术市场- 按类型(中国仓鼠卵巢(CHO)、人类胚胎肾(HEK))、应用(单株抗体、重组蛋白)、最终用途(生物製药公司、CMO 和CDMO)与预测,2023 -2032 年Mammalian Cell Fermentation Technology Market - By Type (Chinese Hamster Ovary (CHO), Human Embryonic Kidney (HEK)), Application (Monoclonal Antibodies, Recombinant Proteins), End-use (Biopharmaceutical Companies, CMOs & CDMOs) & Forecast, 2023-2032 |
受疫苗、单株抗体和治疗性蛋白等生物製药需求飙升的支持,哺乳动物细胞发酵技术产业规模预计 2023 年至 2032 年复合年增长率将达到 8.4%。对以高产量和最小污染风险为特征的高效且可扩展的生产流程的需求推动了该技术的采用。
此外,人们越来越关注个人化医疗和再生疗法。例如,2023 年 4 月,富士通和 BSC 宣布合作,以改进他们在个人化医疗和量子计算方面的研究。这个因素,加上生物加工技术的进步,包括一次性生物反应器和改进的细胞系,以简化生物製品的製造,将刺激市场动态。
哺乳动物细胞发酵技术市场根据类型、应用、最终用途和地区进行分类。
重组蛋白细分市场从 2023 年到 2032 年将实现 9.3% 的复合年增长率,因为它们广泛应用于生物製药行业,用于各种治疗、诊断和研究目的。哺乳动物细胞发酵技术提供了生产高品质重组蛋白的理想平台,因为它能够促进翻译后修饰,例如糖基化,这对于这些蛋白质的功能至关重要。随着生物製药研究的不断多样化和扩展,重组蛋白应用领域将蓬勃发展。
生物製药公司领域预计 2023 年至 2032 年复合年增长率为 8%。这些公司负责开发和製造创新生物製剂,用于治疗多种疾病,包括癌症、自体免疫疾病和传染病。哺乳动物细胞发酵技术的灵活性、可扩展性和可靠性对于寻求优化其生产流程的生物製药公司来说非常有价值。大规模生产生物製剂的能力,同时确保产品品质和一致性,使该技术成为这些公司的重要资源。
由于人口成长、医疗保健支出增加以及对先进疗法的需求不断增长,亚太地区哺乳动物细胞发酵技术产业规模预计 2023 年至 2032 年复合年增长率将达到 9.5%。该地区拥有许多热衷于采用最先进技术的生物製药公司、研究机构和合约製造组织。随着监管途径变得更加精简和有利,亚太地区市场预计在不久的将来将大幅成长。
Mammalian cell fermentation technology industry size is expected to record 8.4% CAGR from 2023 to 2032 backed by the soaring demand for biopharmaceuticals, including vaccines, monoclonal antibodies, and therapeutic proteins. The need for efficient and scalable production processes, characterized by high yields and minimal contamination risks, has fueled the adoption of this technology.
Furthermore, there is growing focus on personalized medicine and regenerative therapies. For instance, in April 2023, Fujitsu and BSC announced a collaboration to improve their research on personalized medicine and quantum computing. This factor, along with the advancements in bioprocessing techniques, including single-use bioreactors and improved cell lines, for streamlining the manufacturing of biologics, will stimulate the market dynamics.
The mammalian cell fermentation technology market is classified based on type, application, end-use, and region.
The recombinant proteins segment will record 9.3% CAGR from 2023 to 2032 as they are widely employed in the biopharmaceutical industry for a myriad of therapeutic, diagnostic, and research purposes. Mammalian cell fermentation technology offers an ideal platform to produce high-quality recombinant proteins due to its ability to facilitate post-translational modifications, such as glycosylation, essential for the functionality of these proteins. The recombinant proteins application segment is poised to flourish as biopharmaceutical research continues to diversify and expand.
The biopharmaceutical companies segment is anticipated to observe 8% CAGR during 2023-2032. These companies are responsible for developing and manufacturing innovative biologics that cater to a wide range of diseases, including cancer, autoimmune disorders, and infectious diseases. The flexibility, scalability, and reliability of mammalian cell fermentation technology are highly valuable to biopharmaceutical firms seeking to optimize their production processes. The ability to produce biologics on a large scale, while ensuring product quality and consistency, positions the technology as a vital resource for these companies.
Asia Pacific mammalian cell fermentation technology industry size is predicted to witness 9.5% CAGR from 2023 to 2032 driven by a growing population, increasing healthcare expenditure, and a rising demand for advanced therapeutics. The region is home to numerous biopharmaceutical companies, research institutes, and contract manufacturing organizations that are keen to incorporate state-of-the-art technologies. As regulatory pathways become more streamlined and favorable, the APAC market is expected to experience substantial growth in the near future.